Biomea Fusion, Inc.

The momentum for this stock is not very good. Biomea Fusion, Inc. is not a good value stock. Biomea Fusion, Inc. is not very popular among insiders. Biomea Fusion, Inc. is a mediocre stock to choose.

News

Biomea Fusion's BMF-219: A Catalyst for Growth in Metabolic Disease Treatment and Oncology

TipRanks Financial Blog Naureen Quibria, an analyst from Capital One Financial, has initiated a new Buy rating on Biomea Fusion (BMEA). Naureen Quibria's rating is based o...\n more…

Biomea Fusion initiated with bullish view at Capital One

The Fly See the rest of the story here.\n\nthefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...\n more…

Biomea Fusion price target lowered by $23 at Citi, here's why

Following a 63% decline over last year, recent gains may please Biomea Fusion, Inc. (NASDAQ:BMEA) institutional owners

Simply Wall St Key Insights Institutions' substantial holdings in Biomea Fusion implies that they have significant influence over the...\n more…

Wall Street Analysts Think Biomea Fusion (BMEA) Could Surge 317.86%: Read This Before Placing a Bet

Zacks Investment Research Biomea Fusion, Inc. (BMEA) closed the last trading session at $5.71, gaining 2% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets set by Wall...\n more…

Biomea Fusion, Inc. Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4)

Globe Newswire REDWOOD CITY, Calif., Aug. 01, 2024 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (Nasdaq: BMEA) ( Biomea or the Company ), a clinical stage biopharmaceutical company focused on the discovery and...\n more…